Daravita ANDA Form Case 114-Cv-01118-UNA
of 1
description
Case 114-Cv-01118-UNADaravita (Alkermes) Patent Infringement Case Against Actavis with respect to the Manufacturing of Generic ZohydroER.ZohydroER is licensed by Zogenix and has exclusivity until fall 2016 by the FDA.
Transcript of Daravita ANDA Form Case 114-Cv-01118-UNA
-
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
DARAVITA LIMITED,
Plaintiff,
v.
ACTAVIS LABORATORIES FL, INC.,
ANDRX CORPORATION, ACTAVIS
PHARMA, INC., and ACTAVIS, INC.,
Defendants.
)
)
)
)
)
)
)
)
)
)
)
C.A. No. ______________
SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)
Plaintiff hereby provides the information below with respect to the deadlines set forth in
21 U.S.C. 355(j):
Date Patentee(s) Received Notice: August 12, 2014
Date of Expiration of Patent: U.S. Patent No. 6,228,398: Nov. 1, 2019
U.S. Patent No. 6,902,742: Nov. 1, 2019
Thirty-Month Stay Deadline: February 12, 2017
September 3, 2014
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
/s/ Maryellen Noreika Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
Jeremy A. Tigan (#5239)
1201 N. Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
Attorneys for Daravita Limited
8498534
Case 1:14-cv-01118-UNA Document 3 Filed 09/03/14 Page 1 of 1 PageID #: 45
